Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor
Abstract
Share and Cite
Hiroshima, S.; Nyuzuki, H.; Sasaki, S.; Ogawa, Y.; Nagasaki, K. Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor. Children 2021, 8, 293. https://doi.org/10.3390/children8040293
Hiroshima S, Nyuzuki H, Sasaki S, Ogawa Y, Nagasaki K. Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor. Children. 2021; 8(4):293. https://doi.org/10.3390/children8040293
Chicago/Turabian StyleHiroshima, Shota, Hiromi Nyuzuki, Sunao Sasaki, Yohei Ogawa, and Keisuke Nagasaki. 2021. "Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor" Children 8, no. 4: 293. https://doi.org/10.3390/children8040293
APA StyleHiroshima, S., Nyuzuki, H., Sasaki, S., Ogawa, Y., & Nagasaki, K. (2021). Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor. Children, 8(4), 293. https://doi.org/10.3390/children8040293